Since joining EEBIC in 2022, Abscint has positioned itself as a leader in molecular imaging. The company develops cutting-edge technologies to improve cancer detection and diagnosis, including breast cancer. These innovative solutions offer patients faster and more personalized treatments.
Under the leadership of Karine Clauwaert, Abscint has achieved remarkable growth, expanding from a team of five to eight employees. The flexible office spaces at EEBIC have allowed the company to adapt easily to this expansion – a crucial advantage for a fast-growing start-up.
Women in Science and Entrepreneurship: Karine also shares her perspective on the role of women in these fields. She highlights the importance of overcoming self-imposed limitations and the value of diverse teams. These varied perspectives enrich both the workplace and the success of projects.
📽️ Curious about Karine Clauwaert and Abscint’s breakthroughs?
Watch the full interview below!